Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Decrease in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 187,291 shares, a drop of 43.3% from the May 31st total of 330,345 shares. Approximately 8.0% of the company’s shares are sold short. Based on an average daily trading volume, of 370,446 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD traded up $0.02 during trading on Thursday, reaching $0.77. 29,417 shares of the company were exchanged, compared to its average volume of 339,105. The business’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $2.23. Aethlon Medical has a 12-month low of $0.65 and a 12-month high of $27.40. The firm has a market capitalization of $1.83 million, a PE ratio of -0.06 and a beta of 1.41.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent quarter. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.